BioDelivery Sciences partners with Quintiles for anticipated drug launch

03/27/2014 11:56 AM

02/15/2015 10:45 AM

BioDelivery Sciences International announced Thursday that it has entered into an agreement with Quintiles to have it support the anticipated launch of Bunavail, BioDelivery Sciences treatment for opioid dependence.

Assuming the drug wins regulatory approval this summer, Raleigh-based BioDelivery Sciences intends to launch the drug in the third quarter of this year.

Under its agreement with Quintiles, the Durham pharmaceutical services company will support the recruitment, training and deployment of a sales force to reach physicians. BioDelivery Sciences estimates nearly 5,000 physicians are responsible for roughly 90 percent of the prescriptions for treatment of opioid dependence.

BioDelivery Sciences expects to hear back from the Food and Drug Administration about its new drug application for Bunavail on June 7.

In February, the company raised $60 million by selling a block of shares to a group of institutional investors. The proceeds are to pay for the commercialization of Bunavail.

Join the Discussion

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service